

Glycoform Limited
Unit 44C
Milton Park
Abingdon
Oxford
OX14 4RU



17th July 2006

Press Release

Research Collaboration between Cambridge Antibody Technology and Glycoform Ltd

Glycoform today announces that it has entered into a research collaboration with Cambridge Antibody Technology (CAT) to evaluate Glycoform's protein glycosylation technology and its application to monoclonal antibodies to improve antibody-dependant cell-mediated cytotoxicity (ADCC).

"We are delighted to have taken this relationship forward so that we can undertake research work with CAT in monoclonal antibodies" said Michael Short, CEO Glycoform Ltd, adding "In addition to our own in-house pipeline, including treatments for anaemia and Gaucher Disease, we are now looking to build external relationships to support the next stage of the company's development and growth."

No further details on the agreement were disclosed.

For further information:

Glycoform Ltd: +44 (0) 1235 820 463

Michael Short, Chief Executive Officer

-ENDS-

About Glycoform

Glycoform Ltd is a biotechnology company developing next generation glycoproteins. Glycoform uses its capabilities in the design and synthesis of homogeneous sugars (oligosaccharides) combined with site directed conjugation techniques to add these sugars to proteins to deliver optimised and uniform next generation glycoprotein therapeutics. The flexibility of the approach means that all proteins from any expression system may now be glycosylated with both naturally occurring and novel sugar structures. The

Company's most advanced development candidate is GLY510, a hormone treatment for anaemia. Glycoform was founded in 2002 and is based near Oxford in the UK.

More information: www.glycoform.co.uk

About Cambridge Antibody Technology (CAT)

- Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients' lives. Following the recent acquisition of CAT by AstraZeneca, CAT is a subsidiary of the AstraZeneca group of companies. CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA.
- CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs.
- More information: www.cambridgeantibody.com